⌕
Oruka Therapeutics · ORKA · Nasdaq
Tenet 54 · Mixed
Compare
$96.32−2.94%At closeTenet 54 · Mixed
$96.32−2.92 (−2.94%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Oruka Therapeutics (ORKA) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice

10 figures withheld by our checks. Each blank figure names its reason.

Business enginePre-revenue: no positive revenue in any year through FY25, so the growth and margin read is withheld. Worth your attention in FY25: Capex step-up ($209.0K). Visible in the receipts below.
The lines that matter · FY19–FY25
Revenue ($M)—
0.0
FY19→FY25CAGR —
Net income ($M)▼962.2%
−105.4
FY19→FY25CAGR —
Free cash flow ($M)▼710.1%
−88.4
capex stepped upCAGR —
What the receipts whisper · what a headline number hides
Share count
+0.0%

45.8mn → 45.8mn diluted shares since FY25. Broadly flat, so EPS moves with net income rather than with the share count.

Capex step-up
$209.0K

▲10350% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.

What the income statement says · FY19–FY25
Where every revenue dollar goes · FY25 ($M)0.0Revenue0.0COGS0.0Gross profit−100.6R&D−21.4SG&A−122.1Op income16.6Tax & other−105.4Net income

Margin trend · direction beats level
108530%sector median net margin ~3%FY19FY25

This filer reports no gross profit or operating income line, so those margins are not drawn.

The receipt · income statement · FY19–FY25 USD thousands except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 0.3191, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis.
USD thousands except per-share & ratios
Line itemTTM †FY25FY22FY21FY20FY19YoYCAGR 19→25
Revenue & profitability
Revenue
—0.00.00.00.00.0——
Cost of revenue
—0.00.00.00.00.0——
Gross profit
—0.00.00.00.00.0——
Research & development
153,738.0100,640.04,749.013,832.04,992.01,833.0▲2019.2%+172.2%
Selling, general & admin
29,370.021,411.05,847.05,503.04,774.03,981.0▲266.2%+52.3%
Total operating expenses
183,108.0122,051.010,596.019,335.09,766.05,814.0▲1051.9%+114.1%
Operating incomefeeds ROC rank
−183,108.0−122,051.0−10,596.0−19,335.0−9,766.0−5,814.0▼1051.9%—
Other income, net
30,534.016,618.0670.013.019.0165.0——
Pretax income
−152,574.0−105,433.0−9,926.0−19,322.0−9,747.0−5,649.0▼962.2%—
Income tax
————−9.0−167.0——
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−152,574.0−105,433.0−9,926.0−19,322.0−9,738.0−5,482.0▼962.2%—
Per share
Diluted EPSbuyback-sensitive
—A—A—A—A—A—A——
Diluted shares (mn)
143.3745.751.201.160.390.11▲3709.9%+351.5%
Margins
† TTM = trailing four quarters through 2026-09-30.A Withheld by our checks.
FY10 – FY18 · 9 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 9 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-03-12 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.